Mika Kakefuda Derynck net worth and biography

Mika Derynck Biography and Net Worth

Director of Enliven Therapeutics

Mika is the Chief Medical Officer at Amunix Pharmaceuticals and has over 25 years of experience in drug development and expertise in oncology, covering multiple therapeutic modalities, tumor types and development phases. Amunix Pharmaceuticals has been acquired by Sanofi SA and she remains the Chief Medical Officer for Amunix within Sanofi R&D. Previously, Mika worked at Genentech, most recently as Global Head for Cancer Immunotherapy, GI/GU Cancers, Angiogenesis Franchises and China Oncology Development. Previous to that she was Global Head of the Breast Cancer Franchise for Development. While at Genentech, she oversaw the approval or global development of more than a dozen drugs. She was previously a Senior Group Medical Director of Exploratory Clinical Development at Genentech, leading the development of several early-stage programs.

Prior to joining Genentech, Mika was an Assistant Clinical Professor in the Department of Cellular and Molecular Oncology and Division of Hematology/Oncology at the University of California, San Francisco.

Mika received an M.D. from Boston University School of Medicine and a B.A. in Biology from Boston University. She completed an Internal Medicine residency at Johns Hopkins Hospital and a fellowship in Medical Oncology at the University of California, San Francisco.

What is Mika Kakefuda Derynck's net worth?: The estimated net worth of Mika Kakefuda Derynck is at least $5.27 million as of August 4th, 2026. Dr. Derynck owns 87,373 shares of Enliven Therapeutics stock worth more than $5,265,971 as of August 7th. This net worth estimate does not reflect any other assets that Dr. Derynck may own. Learn More about Mika Kakefuda Derynck's net worth.
How do I contact Mika Kakefuda Derynck?: The corporate mailing address for Dr. Derynck and other Enliven Therapeutics executives is 309 Beacon Street Suite 300 Office 341, Brookline MA, 02446. Enliven Therapeutics can also be reached via phone at 617-927-9989 and via email at [email protected]. Learn More on Mika Kakefuda Derynck's contact information.
Has Mika Kakefuda Derynck been buying or selling shares of Enliven Therapeutics?: In the last ninety days, Mika Kakefuda Derynck has sold $9,561,046.95 in shares of Enliven Therapeutics stock. Most recently, Mika K. Derynck sold 158,795 shares of the business's stock in a transaction on Tuesday, August 4th. The shares were sold at an average price of $60.21, for a transaction totalling $9,561,046.95. Following the completion of the sale, the director now directly owns 87,373 shares of the company's stock, valued at $5,260,728.33. Learn More on Mika Kakefuda Derynck's trading history.
Who are Enliven Therapeutics' active insiders?: Enliven Therapeutics' insider roster includes Rahul Ballal (Director), Mika Derynck (Director), Rishi Gupta (Director), Richard Heyman (Chairman of the Board of Directors), Benjamin Hohl (Chief Financial Officer and Head of Corporate Development), Samuel Kintz (Co-founder, Chief Executive Officer, and Member of the Board of Directors), Lori Kunkel (Director), Joseph Lyssikatos (Co-founder, Chief Scientific Officer), and Anish Patel (Co-founder and Chief Operating Officer). Learn More on Enliven Therapeutics' active insiders.
Are insiders buying or selling shares of Enliven Therapeutics?: In the last twelve months, insiders at the sold shares 38 times. They sold a total of 566,325 shares worth more than $20,128,241.76. The most recent insider tranaction occured on August, 4th when Director Mika K Derynck sold 158,795 shares worth more than $9,561,046.95. Insiders at Enliven Therapeutics own 3.0% of the company. Learn More about insider trades at Enliven Therapeutics.
Information on this page was last updated on 8/4/2026.

Mika Kakefuda Derynck Insider Trading History at Enliven Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/4/2026	Sell	158,795	$60.21	$9,561,046.95	87,373

Mika Kakefuda Derynck Buying and Selling Activity at Enliven Therapeutics

Enliven Therapeutics Company Overview

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.

Today's Range

Now: $60.27

$59.11

$61.86

50 Day Range

MA: $48.21

$33.63

$61.11

2 Week Range

Now: $60.27

$14.78

$62.32

Volume

1,679,203 shs

Average Volume

962,013 shs

Market Capitalization

$3.67 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.27